Hans-Günter Zerwes

Title: The Innovations of Hans-Günter Zerwes

Introduction

Hans-Günter Zerwes is a notable inventor based in Lörrach, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of transgenic animals and therapeutic applications. With a total of 2 patents, his work has implications for both research and medical treatments.

Latest Patents

One of his latest patents involves the creation of transgenic animals for studying the regulation of genes. This patent describes a transgenic non-human animal, such as a transgenic mouse, that comprises a polynucleotide encoding a soluble marker protein functionally linked to a regulatory sequence of an endogenous gene encoding E-selectin. The patent also outlines methods for detecting modulators of the E-selectin gene using these transgenic animals and cultured cells derived from them.

Another significant patent by Zerwes focuses on the use of 40-O-(2-hydroxy)ethyl-rapamycin for the treatment of restenosis and other disorders. This invention relates to the prevention or treatment of neointimal proliferation and thickening, restenosis, and vascular occlusion following vascular injury.

Career Highlights

Zerwes is currently associated with Novartis AG, a leading global healthcare company. His work at Novartis has allowed him to further his research and contribute to innovative solutions in the medical field.

Collaborations

Throughout his career, Hans-Günter Zerwes has collaborated with esteemed colleagues, including Walter Schuler and Hendrik Schuurman. These collaborations have enhanced the scope and impact of his research.

Conclusion

Hans-Günter Zerwes is a prominent inventor whose work in biotechnology has led to valuable patents that advance our understanding of gene regulation and therapeutic treatments. His contributions continue to influence the fields of research and medicine.